Kiniksa Pharmaceuticals International PLC Class A KNSA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Kiniksa Pharmaceuticals to Present at Jefferies Global Healthcare Conference in London
Kiniksa Pharmaceuticals Reports Third Quarter 2026 Financial Results and Recent Portfolio Execution
Kiniksa Pharmaceuticals to Report Third Quarter 2026 Financial Results on October 27, 2026
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference
Kiniksa Pharmaceuticals Gets Orphan Drug Designation for KPL-387
Trading Information
- Previous Close Price
- $95.02
- Day Range
- $93.49–96.15
- 52-Week Range
- $37.02–99.31
- Bid/Ask
- $93.45 / $97.00
- Shares Outstanding
- 78.57M
- Market Cap
- $7.52B
- Volume/Avg
- 581,163 / 663,087
Key Statistics
- Price/Earnings (Normalized)
- 68.95
- Price/Sales
- 8.43
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.21%
Company Profile
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Growth
- Total Number of Employees
- 366
- Website
- https://www.kiniksa.com
Valuation
Metric | KNSA |
|---|---|
Price/Earnings (Normalized) | 68.95 |
Price/Book Value | 10.58 |
Price/Sales | 8.43 |
Price/Cash Flow | 48.54 |
Price/Earnings
KNSA
Financial Strength
Metric | KNSA |
|---|---|
Quick Ratio | 3.12 |
Current Ratio | 3.91 |
Interest Coverage | — |
Quick Ratio
KNSA
Profitability
Metric | KNSA |
|---|---|
Return on Assets (Normalized) | 17.13% |
Return on Equity (Normalized) | 23.31% |
Return on Invested Capital (Normalized) | 22.97% |
Return on Assets
KNSA
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|@>fMr%# | LOCK|>n>% | $73B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|$D#j@>$ | LOCK|$RTrB | $50B | |||
| Haleon PLC ADR HLN | LOCK|>y%N><& | LOCK|%# | $40B | |||
| Zoetis Inc Class A ZTS | LOCK|dC^mlhC | LOCK|H^& | $34B | |||
| Viatris Inc VTRS | LOCK|YD<P%x% | LOCK|S# | $24B | |||
| Elanco Animal Health Inc ELAN | LOCK|^y | LOCK|$^ | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|#^%@cK^ | LOCK|y@v | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|%wV%Jr | LOCK|bX | $5B | |||
| Perrigo Co PLC PRGO | LOCK|j>^#xb! | LOCK|^?n | $2B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|n!#$P? | LOCK|FPVc | $2B |
United States